DUBLIN, Nov. 27, 2025 (Globe Newswire) — The ‘Human Vaccines – Global Strategic Business Report’ report has been added. ResearchAndMarkets.com Offerings.
The global market for human vaccines was valued at USD 46.9 billion in 2024 and is projected to reach USD 71.4 billion by 2030, growing at a CAGR of 7.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts to help you make informed business decisions.
Human vaccines are one of the greatest achievements in public health, providing protection against a myriad of infectious diseases by training the immune system to recognize and fight pathogens. Vaccines, which consist of antigens that mimic disease-causing microorganisms, are critical to preparing the immune system to quickly and effectively fight disease. This mechanism has successfully eradicated and reduced many life-threatening diseases such as smallpox and polio, significantly reducing morbidity and mortality worldwide. Vaccines not only protect individuals, but also contribute to herd immunity, preventing the spread of infection throughout communities and thereby ensuring population health globally.
What are the driving forces behind the growth of the human vaccines market?
The growth of the human vaccines market is driven by several factors, including the increasing prevalence of infectious diseases, rising global health awareness, and advances in vaccine research and development. Increased funding and investment by governments and the World Health Organization to eliminate infectious diseases has significantly contributed to expansion and innovation in the vaccine sector.
The COVID-19 pandemic has particularly highlighted the critical role of vaccines in global health security and led to unprecedented public-private partnerships focused on vaccine development and distribution. Additionally, demographic factors such as an aging population and an increase in chronic health conditions that increase susceptibility to infectious diseases require continued vaccine development and dissemination. Taken together, these moves highlight the important role of vaccines in modern medicine and public health and ensure continued investment and research in this important area.
Exploring new frontiers: Innovations that improve vaccine efficacy and safety
The vaccine technology landscape is constantly evolving, incorporating new methods that promise better protection and safety. Traditional vaccine strategies are effective, but are now being enhanced by cutting-edge approaches such as mRNA vaccines and recombinant technology. These innovations provide precise targeting and rapid scalability, particularly highlighted by their role in quickly responding to global challenges such as the COVID-19 pandemic. Additionally, the development of adjuvants and improved delivery systems continues to revolutionize vaccine efficacy, expanding the horizon for combating more complex diseases and tailoring immunizations to diverse populations.
Emerging trends reshaping the global vaccine sector
Global demographic and technological trends are reshaping the vaccine industry. Increased international travel and urbanization increase the risk of infectious disease transmission and increase the need for effective vaccination programs. At the same time, increased health awareness and improved health infrastructure are accelerating vaccine uptake globally, especially in traditionally underserved areas. Technological advances in healthcare, such as digital immunization tracking and AI, are also improving the reach and efficiency of vaccination campaigns, ensuring broader and more effective coverage.
Report features:
- Comprehensive market data: Independent analysis of annual sales and market forecasts in million USD from 2024 to 2030.
- Detailed regional analysis: Detailed insights into key markets including the US, China, Japan, Canada, Europe, Asia Pacific, Latin America, Middle East and Africa.
- Company Profile: ALK – Covers companies such as Abello A/S, Altimmune, Inc., Astellas Pharma Inc., Bavarian Nordic A/S, and Bharat Biotech.
- Free Updates: Receive 1 year of free report updates to stay on top of the latest market trends.
Key insights:
- Market Growth: Understand the significant growth trajectory of the intramuscular and subcutaneous administration segment, expected to reach USD 58.7 billion by 2030 at a CAGR of 7.8%. The oral administration segment is also expected to grow at a CAGR of 5.3% during the analysis period.
- Regional analysis: Gain insight into the US market, valued at $12.4 billion in 2024, and the Chinese market, expected to grow at an incredible 11.7% CAGR and reach $16.8 billion by 2030. See growth trends in other key regions such as Japan, Canada, Germany, and Asia Pacific.
Report scope
- segment:Routes of administration (intramuscular and subcutaneous, oral, other routes of administration); techniques (conjugates, recombinant, inactivated and subunits, live attenuated, other techniques).
- Geographic region/country:World; United States; Canada; Japan; China; Europe (France, Germany, Italy, United Kingdom, Spain, Russia, and Rest of Europe); Asia Pacific (Australia, India, South Korea, and Rest of Asia Pacific). Latin America (Argentina, Brazil, Mexico, and the rest of Latin America). Middle East (Iran, Israel, Saudi Arabia, United Arab Emirates, and other Middle Eastern regions); and Africa.
Key attributes:
| report attributes | detail |
| Number of pages | 262 |
| Forecast period | 2024-2030 |
| Estimated market value in 2024 (USD) | $46.9 billion |
| Projected market value to 2030 (USD) | $71.4 billion |
| compound annual growth rate | 7.3% |
| Target area | global |
Main topics covered:
Market overview
- Trade shocks, uncertainty, and the structural rewiring of the global economy
- What impact will President Trump’s tariffs have on the market? The big question on everyone’s mind
- Latest information on the world economy
- Human Vaccines – Market Share Percentage of Global Major Competitors in 2025 (E)
- Competitive Market Presence – Strong/Active/Niche/Minor (E) for Players Worldwide in 2025
Market trends and drivers
- Advances in genetic and recombinant technology expand vaccine effectiveness
- Global demand for pediatric and adult vaccines grows
- Increasing awareness and education about vaccine-preventable diseases
- Integrating AI and machine learning in vaccine development
- Innovations in vaccine delivery systems and adjuvants
- Vaccination programs in public health systems increase vaccine use and uptake among susceptible populations
- Emergence of new pathogens increases demand for new vaccines
- Vaccines to prevent HIV are still under development
- Interest in research and development of personalized cancer vaccines increases
Focus on carefully selected players
- ALK – Avello A/S
- Ultimune Co., Ltd.
- Astellas Pharma Inc.
- Bavarian Nordic A/S
- Bharat Biotech
- BiondVax Pharmaceuticals Co., Ltd.
- GlaxoSmithKline
- Hualan Biotechnology Co., Ltd.
- Janssen Pharma Co., Ltd.
- Medimmune
- Mitsubishi Tanabe Pharma
- Pfizer Inc.
- Sanofi Pasteur SA
- Sekyrus
- Serum Institute of India Ltd.
- SK Bioscience
- Takeda Pharmaceutical Company Limited
- Zydus Cadira
For more information on this report, please visit https://www.researchandmarkets.com/r/fe9x7l.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.
